Shares of Theralase Technologies Inc. (CVE:TLT – Get Free Report) fell 7.4% during mid-day trading on Friday . The company traded as low as C$0.23 and last traded at C$0.25. 287,012 shares were traded during mid-day trading, an increase of 141% from the average session volume of 119,241 shares. The stock had previously closed at C$0.27.
Theralase Technologies Stock Down 7.4 %
The firm has a 50 day moving average price of C$0.27 and a 200-day moving average price of C$0.21. The firm has a market cap of C$61.39 million, a PE ratio of -12.50 and a beta of 1.36. The company has a current ratio of 1.21, a quick ratio of 3.40 and a debt-to-equity ratio of 20.58.
About Theralase Technologies
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
See Also
- Five stocks we like better than Theralase Technologies
- How to Capture the Benefits of Dividend Increases
- XPO Stock Gains Momentum as U.S. Trade Outlook Evolves
- Why Are These Companies Considered Blue Chips?
- CarMax Gets in Gear: Is Now the Time to Buy?
- How to Use the MarketBeat Stock Screener
- Qubit Combat: 2 Stocks Battle for Quantum Supremacy
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
